Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
ACS Med Chem Lett ; 1(2): 64-9, 2010 May 13.
Artigo em Inglês | MEDLINE | ID: mdl-24900178

RESUMO

Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (∼10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.

2.
J Med Chem ; 52(9): 2806-17, 2009 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-19371095

RESUMO

Hepatitis C virus (HCV) infection is a global health crisis leading to liver cirrhosis, hepatocellular carcinoma, and liver failure in humans. Recently, we disclosed the discovery of Boceprevir, SCH 503034 (1), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that is currently undergoing phase III clinical trials. Our efforts toward a second generation HCV NS3 serine protease inhibitor were directed at improving the overall profile of the inhibitor. This article will elaborate on our studies leading to the discovery of new P4 modified inhibitors with enhanced potency and improved oral bioavailability. Thus, introduction of ether and carbamate-derived P4 moieties resulted in improving the replicon potency significantly. Incorporation of the P' secondary amide residue afforded significant improvement in pharmacokinetic properties. Combining the preferred moieties, identified from comprehensive SAR studies, resulted in inhibitors that displayed superior potency and very good oral as well as target organ exposure in rats.


Assuntos
Descoberta de Drogas , Hepacivirus/enzimologia , Inibidores de Proteases/farmacologia , Inibidores de Proteases/farmacocinética , Proteínas não Estruturais Virais/antagonistas & inibidores , Amidas/química , Animais , Modelos Moleculares , Conformação Molecular , Inibidores de Proteases/síntese química , Inibidores de Proteases/química , Ratos , Relação Estrutura-Atividade
3.
J Mass Spectrom ; 43(4): 509-17, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18059003

RESUMO

Posaconazole (SCH 56592) is a novel triazole antifungal drug that is marketed in Europe and the United States under the trade name 'Noxafil' for prophylaxis against invasive fungal infections. SCH 56592 was discovered as a possible active metabolite of SCH 51048, an earlier lead. Initial studies have shown that serum concentrations determined by a microbiological assay were higher than those determined by HPLC from animals dosed with SCH 51048. Subsequently, several animals species were dosed with (3)H-SCH 51048 and the serum was analyzed for total radioactivity, SCH 51048 concentration and antifungal activity. The antifungal activity was higher than that expected based on SCH 51048 serum concentrations, confirming the presence of active metabolite(s). Metabolite profiling of serum samples at selected time intervals pinpointed the peak that was suspected to be the active metabolite. Consequently, (3)H-SCH 51048 was administered to a large group of mice, the serum was harvested and the metabolite was isolated by extraction and semipreparative HPLC. LC-MS/MS analysis suggested that the active metabolite is a secondary alcohol with the hydroxyl group in the aliphatic side chain of SCH 51048. All corresponding monohydroxylated diastereomeric mixtures were synthesized and characterized. The HPLC retention time and LC-MS/MS spectra of the diastereomeric secondary alcohols of SCH 51048 were similar to those of the isolated active metabolite. Finally, all corresponding individual monohydroxylated diasteriomers were synthesized and evaluated for in vitro and in vivo antifungal potencies, as well as pharmacokinetics. SCH 56592 emerged as the candidate with the best overall profile.


Assuntos
Antifúngicos/análise , Antifúngicos/farmacocinética , Espectrometria de Massas , Triazóis/análise , Triazóis/farmacocinética , Animais , Antifúngicos/sangue , Cromatografia Líquida de Alta Pressão , Cães , Desenho de Fármacos , Macaca fascicularis , Masculino , Camundongos , Camundongos Endogâmicos , Coelhos , Triazóis/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...